Sugi Predict

Sugi Predict / Compounds / SCHEMBL1444893

SCHEMBL1444893

SCHEMBL1444893

O=C(NO)Oc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAD51 Q06609 1/20 0.56
▸ ALDH1A1 P00352 6/20 0.53
▸ MAPT P10636 3/20 0.53
▸ RAB9A P51151 1/20 0.52
▸ SLC1A3 P43003 1/20 0.50
▸ KMT2A Q03164 3/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ TDP1 Q9NUW8 2/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ THRB P10828 1/20 0.49
▸ GFER P55789 1/20 0.49
▸ GAA P10253 2/20 0.48
▸ HTT P42858 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ HSD17B10 Q99714 2/20 0.47
▸ LMNA P02545 1/20 0.47
▸ TP53 P04637 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ ATM Q13315 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2551644 0.83 ALDH1A1 (0.55) RAD51ALDH1A1MAPTRAB9ASLC1A3
SCHEMBL5523592 0.79 ALDH1A1 (0.52) RAD51ALDH1A1MAPTRAB9ASLC1A3
SCHEMBL13303658 0.79 ALDH1A1 (0.52) RAD51ALDH1A1MAPTRAB9ASLC1A3
SCHEMBL721196 0.79 SLC1A3 (0.53) RAD51ALDH1A1MAPTRAB9ASLC1A3
SCHEMBL14336248 0.79 ALDH1A1 (0.52) RAD51ALDH1A1MAPTRAB9ASLC1A3
Phenyl Methylcarbamate SCHEMBL78497 0.79 CYP1A2 (0.57) RAD51ALDH1A1MAPTRAB9ASLC1A3
SCHEMBL9267073 0.79 ALDH1A1 (0.52) RAD51ALDH1A1MAPTRAB9ASLC1A3
SCHEMBL21315898 0.79 ALDH1A1 (0.52) RAD51ALDH1A1MAPTRAB9ASLC1A3
SCHEMBL21892986 0.79 ALDH1A1 (0.52) RAD51ALDH1A1MAPTRAB9ASLC1A3
SCHEMBL3074679 0.79 ALDH1A1 (0.52) RAD51ALDH1A1MAPTRAB9ASLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114641291-A Compositions of small molecule therapeutic compounds 戴尔普尔有限公司 2022-06-17 — — CN claimed
US-9670176-B2 Process for the preparation of zileuton STRIDES SHASUN LIMITED (IN) 2017-06-06 — — US claimed
US-20160376251-A1 Process for the Preparation of Zileuton STRIDES SHASUN LIMITED (IN) 2016-12-29 — — US claimed
CN-102105496-A Method of making carbamate functional materials BASF CORP 2011-06-22 — — CN claimed
WO-2011036680-A2 IMPROVED PROCESS FOR THE PREPARATION OF (±)-1-(1-BENZO[B]THIEN-2-YLETHYL)-1-HYDROXYUREA MSN LABORATORIES LIMITED (IN) 2011-03-31 — — WO claimed
EP-1355887-A1 PYRIMIDINE ACYCLONUCLEOSIDE DERIVATIVES, PREPARATION METHOD AND USE THEREOF UNIVERSITE DE GENEVE (CH) 2003-10-29 — — EP claimed
WO-2002060880-A1 PYRIMIDINE ACYCLONUCLEOSIDE DERIVATIVES, PREPARATION METHOD AND USE THEREOF UNIVERSITE DE GENEVE (CH) 2002-08-08 — — WO claimed
CN-109563088-B Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K and therapeutic uses 密歇根大学董事会 2022-10-11 — — CN disclosed
CN-114641291-A Compositions of small molecule therapeutic compounds 戴尔普尔有限公司 2022-06-17 — — CN disclosed
CN-113100233-B Application of arylhydroxamic acid and derivatives thereof as chitin deacetylase inhibitor and plant antifungal agent 中国农业科学院植物保护研究所 2022-02-08 — — CN disclosed
CN-113100233-A Application of arylhydroxamic acid and derivatives thereof as chitin deacetylase inhibitor and plant antifungal agent 中国农业科学院植物保护研究所 2021-07-13 — — CN disclosed
EP-1613613-B1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS GENZYME CORP (US) 2021-06-02 — — EP disclosed
CN-107922571-B Antifouling composition 巴斯夫聚氨酯特种产品（中国）有限公司 2021-04-30 — — CN disclosed
US-5371264-A Process for preparing N,O-disubstituted hydroxylamine compounds PPG INDUSTRIES, INC. (US) 1994-12-06 — — US disclosed
WO-1994011342-A1 SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS ABBOTT LABORATORIES (US) 1994-05-26 — — WO disclosed
EP-0540673-A4 — — 1994-04-27 — — EP disclosed
EP-0540673-A1 ACETYLENE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY. ABBOTT LAB (US) 1993-05-12 — — EP disclosed
WO-1992001682-A1 ACETYLENE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY ABBOTT LABORATORIES (US) 1992-02-06 — — WO disclosed
US-4160077-A Process of crosslinking unsaturated hydrocarbon polymers employing novel carbamates IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1979-07-03 — — US disclosed
US-3933507-A LIGHT INSENSITIVE SILVER SALT, POLYMETHINE SENSITIZER AGFA-GEVAERT, A.G. (DT) 1976-01-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160376251-A1 Process for the Preparation of Zileuton CYP2B6, UGT1A6, CYP2A6 RAD51 4695/4885ALDH1A1 30/4885MAPT 2460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.